3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺
中文名称 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 |
---|---|
中文同义词 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺;化合物JNJ63533054;JNJ-63533054游离态;(S)-3-氯-N-(2-氧代-2-((1-苯基乙基)氨基)乙基)苯甲酰胺;JNJ 63533054,GPR139激动剂;化合物JNJ63533054,10 MM DMSO 溶液 |
英文名称 | JNJ 63533054 |
英文同义词 | JNJ 63533054;3-Chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]benzamide;CS-2223;JNJ-63533054 (JNJ63533054;Benzamide, 3-chloro-N-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-;JNJ-63533054 >=98% (HPLC);(S)-3-Chloro-N-(2-oxo-2-((1-phenylethyl)amino)ethyl)benzamide;L-tryptophan,blood-brain,oral,CNS,L-phenylalanine,G Protein-Coupled Receptor 139,barrier,JNJ63533054,Inhibitor,GPR139,JNJ-63533054,inhibit |
CAS号 | 1802326-66-4 |
分子式 | C17H17ClN2O2 |
分子量 | 316.78 |
EINECS号 | |
相关类别 | |
Mol文件 | 1802326-66-4.mol |
结构式 | ![]() |
3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 性质
沸点 | 559.7±45.0 °C(Predicted) |
---|---|
密度 | 1.224±0.06 g/cm3(Predicted) |
储存条件 | room temp |
溶解度 | 溶于DMSO(高达35mg/ml)。 |
酸度系数(pKa) | 12.77±0.46(Predicted) |
形态 | 粉末 |
颜色 | 白色至米色 |
旋光性 (optical activity) | [α]/D -89 to -99°, c = 1 in ethanol |
稳定性 | 可在-20°下的DMSO中的溶液保存长达2个月。 |
Target | Value |
human GPR139
(Cell-free assay) | 0.024 μM(Ki) |
mouse GPR139
(Cell-free assay) | 0.054 μM(Ki) |
rat GPR13
(Cell-free assay) | 0.075 μM(Ki) |
JNJ-63533054 specifically activates human GPR139 in the calcium mobilization (EC
50
of 16 nM) and GTPγS binding (EC
50
of 17 nM) assays. JNJ-63533054 also activates the rat and mouse GPR139 receptor with similar potency (rat EC
50
of 63 nM, mouse EC
50
of 28 nM).
In a saturation study for human GPR139, a single population of high-affinity binding sites for [3H] JNJ-63533054 is observed (K
d
of 10 nM). The B
max
value is 26 pmol/mg of protein. Saturation studies for the rat GPR139 and mouse GPR139 yielded K
d
values within the same range (32 nM and 23 nM, respectively; B
max
= 8.5 pmol/mg of protein and 6.2 pmol/mg of protein, respectively).
JNJ-63533054 (3-30 mg/kg; oral administration; once; SD rats) treatment induces a dose-dependent reduction in locomotor activity in the first hour.
The pharmacokinetics of JNJ-63533054 (Compound 7c; 1 mg/kg iv; 5 mg/kg po) in rat is examined. The IV clearance is 53 mL/min/kg, the C
max
is 317 ng/mL (~1 μM), the t
1/2
is 2.5 hours, and JNJ-63533054 is able to cross the blood-brain barrier (BBB) with a brain to plasma ratio (b/p) of 1.2.
Animal Model: | Male Sprague-Dawley rats (350-450 g) |
Dosage: | 3 mg/kg, 10 mg/kg, and 30 mg/kg |
Administration: | Oral administration; once |
Result: | Induced a dose-dependent reduction in locomotor activity in the first hour. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2025/02/08 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 1 mg | 295元 |
2025/02/08 | HY-19838 | 3-氯-N-[2-氧代-2-[[(1S)-1-苯基乙基]氨基]乙基]苯甲酰胺 JNJ-63533054 | 1802326-66-4 | 5mg | 650元 |